Home » Topics » Regulatory » Patents

Patents
RSS

New MAP4K1 inhibitors synthesized at Pfizer

Nov. 26, 2021

Adenosine A2A receptor antagonists identified at Adorx Therapeutics

Nov. 26, 2021

Meiji Seika Pharma divulges histamine H4 receptor antagonists

Nov. 25, 2021

New PADI4 inhibitors synthesized at Gilead

Nov. 25, 2021

IL-17A/IL-17RA interaction modulators patented by Janssen Pharmaceutica

Nov. 25, 2021

New Bcl-2 inhibitors discovered at Prelude Therapeutics

Nov. 25, 2021

Pfizer describes new MAP4K1 inhibitors

Nov. 25, 2021

RaQualia Pharma synthesizes new TRPV4 antagonists

Nov. 24, 2021

Rhizen Pharmaceuticals synthesizes new PARP inhibitors

Nov. 24, 2021

Perha Pharmaceuticals identifies CLK1 and/or CLK4 and/or DYRK1A inhibitors

Nov. 24, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...